National Class Action On Behalf Of Canadian Users Of Rexulti
UPDATE – NOVEMBER 30, 2025
Settlement Approved in the Canadian REXULTI® Class Action
On November 13, 2025 the Superior Court of Québec (the “Court”) approved a settlement reached on behalf of all individuals and the estates and family members of individuals in Canada who were prescribed and took REXULTI® between February 16, 2017 and August 23, 2025 and experienced Compulsive Behaviours and Impulse Control Disorders, namely, compulsive gambling, hypersexuality, compulsive shopping/spending, and binge-eating. The Defendants are the companies responsible for the development, market approval, research, testing, manufacture, and distribution of REXULTI® in Canada.
The Settlement provides for payment of CDN $4.75 million, which will be used to pay compensation for Approved Claims, $118,750.00 in satisfaction of the claims of the Public Health Insurers, the costs of notice and administration, and Court-approved Class Counsel legal fees in the amount of $1,425,000.00, disbursements and taxes. The Court has appointed MNP Ltd. as Administrator of the Settlement.
Settlement Benefits will be distributed in accordance with the Distribution Protocol approved by the Court. Not all Class Members will be eligible for compensation. The Defendants have no role in the determination of Settlement Class Member eligibility to participate in the Settlement or the allocation of benefits available to Settlement Class Members.
The Court has not made any determination of the merits of the claims. The Settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing of the Defendants.
Important Deadline: To be eligible for compensation, Class Members must submit a completed Claim Form to the Administrator no later than July 27, 2026. If you do not file a claim by this deadline, you may not be able to claim a portion of the Settlement and your claim will be extinguished. As a result, it is necessary that you act without delay.
Claim Forms are available for download on the Settlement Website at Rexulticlassactionsettlement.com.
How Do I Get More Information?
If you have questions about the Settlement, your legal rights, how to file a Claim Form, and/or to obtain more information and/or copies of the Settlement Agreement and related documents, please visit the website of Class Counsel, Rochon Genova, or contact the Court Appointed Claims Administrator at the address below:
MNP Ltd. – Class Actions Claims Administration
2000, 112 – 4th Avenue SW
Calgary, AB, T2P 0H3
rexultisettlement@mnp.ca
Toll-Free: 1 (855) 653-0027
Important Documents
Settlement Approval
Short-Form Notice of Settlement Approval – English
Short-Form Notice of Settlement Approval – French
Claim Form – English
Claim Form – French
MONTRÉAL, QC – 29 november 2025 /Newswire/ – Le 13 novembre 2025, la Cour supérieure du Québec (le « Tribunal ») a approuvé un règlement conclu au nom de toutes les personnes au Canada à qui l’on a prescrit et qui ont pris REXULTI® entre le 16 février 2017 et le 23 août 2025 ainsi que leurs successions et les membres de leur famille, et qui ont développé des Comportements compulsifs et des Troubles du contrôle des impulsions, plus précisément le jeu compulsif, l’hypersexualité, les achats compulsifs ou les dépenses incontrôlables et l’hyperphagie. Les Défenderesses sont les sociétés responsables du développement, de l’approbation de la mise en marché, de la recherche, des essais, de la fabrication et de la distribution de REXULTI® au Canada.
Le Règlement prévoit un paiement de 4,75 M$ CA, qui servira à verser une indemnisation à l’égard des Réclamations approuvées, dont 118 750,00 $ seront affectés au règlement des réclamations des Assureurs de soins de santé publics, aux frais de notification et d’administration ainsi qu’aux honoraires juridiques facturés par les Avocats du groupe approuvés par le Tribunal d’un montant de 1 425 000,00 $, plus les débours et les taxes. Le Tribunal a nommé MNP Ltée à titre d’Administrateur du règlement.
Les Indemnités de règlement seront distribuées conformément au Protocole de distribution approuvé par le Tribunal. Les Membres du groupe ne seront pas tous admissibles à une indemnisation. Les Défenderesses n’ont joué aucun rôle dans la détermination de l’admissibilité des Membres du groupe visé par le règlement à participer au Règlement ou dans l’attribution des indemnités offertes aux Membres du groupe visés par le règlement.
Le Tribunal ne s’est pas prononcé sur le bien-fondé des réclamations. Le Règlement constitue un compromis à l’égard des réclamations contestées et ne constitue pas un aveu de responsabilité ou de faute des Défenderesses.
Date limite importante : Pour être admissibles à une indemnisation, les Membres du groupe doivent soumettre un Formulaire de réclamation rempli à l’Administrateur au plus tard le 27 juillet 2026. Si vous ne déposez pas de réclamation d’ici cette date limite, vous pourriez ne pas être en mesure de réclamer une partie du Règlement et votre réclamation sera éteinte. Par conséquent, il est nécessaire d’agir sans délai.
Les Formulaires de réclamation sont disponibles pour téléchargement sur le Site Web du règlement à Rexulticlassactionsettlement.com.
Comment puis-je obtenir des renseignements supplémentaires?
Si vous avez des questions au sujet du Règlement, des droits dont vous disposez en vertu de la loi, de la façon de déposer un Formulaire de réclamation et/ou souhaitez obtenir de plus amples renseignements et/ou des exemplaires de l’Entente de règlement et des documents connexes, veuillez visiter le site Web des Avocats du groupe, Rochon Genova, ou communiquer avec l’Administrateur des réclamations aux coordonnées indiquées ci‑après :
MNP Ltée – Administration des actions collectives
2000, 112 – 4th Avenue SW
Calgary (Alberta) T2P 0H3
rexultisettlement@mnp.ca
Numéro sans frais : 1 (855) 653-0027
La publication du présent avis a été autorisée par la Cour supérieure du Québec
Veuillez ne pas communiquer avec le Tribunal
# # #
______________________________
Source : Rochon Genova
Personne-ressource pour les médias : Joel P. Rochon, Rochon Genova, 1 (866) 881-2292
UPDATE – OCTOBER 20, 2025
Information for Rexulti Settlement Approval Hearing
The Rexulti Settlement Approval Hearing will be proceeding on October 31, 2025 in Room 15.04 of the Superior Court of Quebec located at 1 rue Notre-Dame Est in Montreal. You can also join virtually on Teams using the following link:
| Salle | Lien TEAMS |
| 15.04 | Rejoindre la réunion Microsoft Teams +1 581-319-2194 Canada, Quebec (Numéro payant) (833) 450-1741 Canada (Numéro gratuit) ID de conférence : 436 929 434# Numéros locaux | Réinitialiser le code confidentiel | En savoir plus sur Teams | Options de réunion Rejoindre à l’aide d’un dispositif de vidéoconférence teams@teams.justice.gouv.qc.ca ID de la conférence VTC : 1167171546 Autres instructions relatives à la numérotation VTC |
A copy of the English version of the settlement agreement can be found by clicking here.
A copy of the French version of the settlement agreement can be found by clicking here.
Proposed Settlement Reached in Rexulti Class Action
August 23, 2025 – On December 3, 2021, the Quebec Superior Court of Justice certified a national class action on behalf of REXULTI® Class Members relating to the Defendant drug manufacturers’ alleged failure to warn of the risks of compulsive gambling, hypersexuality, compulsive shopping, and binge eating (“Compulsive Behaviours”) associated with REXULTI®. Notice of authorization of the Class Action was provided on March 15, 2024. The opt-out deadline for Class Members who did not wish to participate in the Class Action expired on May 15, 2024.
The parties have reached a proposed settlement (the “Settlement”) on behalf of all individuals in Canada who were prescribed and took REXULTI® from February 16, 2017 to today’s date and their family members. The Courts have not made any determination of the merits of the claims. The Defendants have denied, and continue to deny, the allegations against them in the Class Action.
For the Settlement to become effective, Court approval is necessary. The Court must be satisfied that the Settlement is fair, reasonable and in the best interests of Class Members. The Settlement Approval Hearing has been scheduled to be heard before the Superior Court of Québec on October 31, 2025.
Class Members who experienced the Compulsive Behaviours for the first time after May 16, 2024, may still opt-out of the Class Action and exclude themselves from the Settlement by delivering an Opt Out form before October 23, 2025 to the Claims Administrator. Opt Out Forms are available at the link below.
If you experienced the Compulsive Behaviours for the first time prior to May 16, 2024 and did not previously opt out of the class action, you may make a request to the Québec Court to opt out of the Settlement by sending a notice to the clerk of the Superior Court of Quebec at 1 Notre-Dame St. East, Montreal, QC, H2Y 1B6, specifying the Court file no. 500-06-000831-160 and attaching a sworn declaration explaining your reasons. If you do not opt out and the Settlement is approved and becomes effective, you will be bound by the Settlement which includes a release of your claims.
The Short-Form and Long-Form Notices are available at the links below:
The Opt-Out Forms are available in both English and French at the links below:
The judgment of the Honourable Justice Nollet of the Superior Court of Quebec approving the notices and scheduling the Settlement Approval Hearing is available at the link below:
Settlement Agreement (English)
Update: March 4, 2024 – A National Class Action has been authorized by the Superior Court of Quebec on behalf of all persons in Canada who were prescribed and used the prescription antipsychotic drug REXULTI during the Class Period starting from February 16, 2017 and who developed one or more of the following Compulsive Behaviours and Impulse Control Disorders: Compulsive Gambling, Hypersexuality, Binge eating, and Compulsive shopping and/or spending.
If you were prescribed and used REXULTI during the Class Period and developed one or more of the Compulsive Behaviours or Impulse Control Disorders described above, your rights are affected by this action. If you wish to remain in the lawsuit, you don’t need to take any further steps at this time. If you wish to exclude yourself from the lawsuit, you must deliver a signed Opt-Out Form by May 15, 2024 by courier, registered or certified mail, to Clerk of the Superior Court of Quebec, Montreal Courthouse, 1 Notre-Dame Street East, Room 1.120, Montreal (Quebec) H2Y 1B6 and reference Court File No. 500-06-000948-188.
Please see below for links to the relevant documents including the Opt-Out Forms in English and French:
Rexulti Long-Form Notice (English)
Rexulti Short-Form Notice (English)
Rexulti Long-Form Notice (French)
Rexulti Short-Form Notice (French)
Opt-Out Form (English)
Opt-Out Form (French)
Rectified Judgment Approving the Authorization Notices and Notice Plan – Feb. 29, 2024
On October 9, 2018, Rochon Genova and Woods commenced a proposed national class action on behalf of all person in Canada who have been prescribed and ingested the antipsychotic drug Rexulti.
Rexulti is the trademark for the drug, brexpiprazole. Rexulti was approved as treatment for schizophrenia in Canada in February 2017, and as treatment for depression in February 2019.
The claim alleges that Otsuka and Lundbeck – the pharmaceutical companies responsible for developing and marketing Rexulti – failed to provide Canadian uses with adequate and timely warnings about the increased risk of impulse control disorders and compulsive behaviours, such as compulsive gambling, compulsive shopping/spending, hypersexuality and binge-eating.
Rexulti is a partial dopamine agonist that is alleged to be substantially similar to the antipsychotic drug aripiprazole (marketed under the trade names Abilify and Abilify Maintena). Abilify and Abilify Maintena were approved in Canada in 2009 and 2014, and have also been associated with impulse control disorders and compulsive behaviours.
Otsuka developed Abilify and Abilify Maintena and has been commercializing and marketing them in Canada along with Bristol-Myers Squibb Canada Co. and Lundbeck Canada Inc., respectively. The claim alleges that the Otsuka and Lundbeck companies intentionally developed Rexulti to be substantially similar to Abilify, because Abilify was losing patent protection. The similarity in the chemical structures of Rexulti and Abilify/Abilify Maintena was noted in the Health Canada Summary Basis of Decision for Rexulti.
This action was commenced in the Quebec Superior Court of Justice in Montreal. Rochon Genova and Woods are seeking authorization of this action as a class action.
The claims have not yet been proven in court. For more information about this proposed class action, please contact Jon Sloan at 1-866-881-2292 ext. 2990 or [email protected]